361 HCT/P, 510(k), PMA or BLA: how to check a skin substitute's FDA status
The products Medicare calls skin substitutes reach the market by four main FDA routes: as human tissue regulated solely under section 361 (a 361 HCT/P), as a device cleared through a 510(k), as a device approved through a PMA, or as a biological product licensed under a BLA. The route determines what paperwork exists, which FDA database lists the product and how CMS categorizes it for Medicare payment. This post shows how the four differ on paper and how to check a product's status yourself.
Why the status matters to a clinic
- CMS uses it to set the Medicare payment category. In its fact sheet on the CY 2026 Physician Fee Schedule final rule, CMS said it was aligning "skin substitute categorization consistent with their FDA regulatory status, such as 361 Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P) and the device types: Pre-Market Approvals (PMAs) and 510(k)s." The final rule describes the policy as one that "does not apply to biological products licensed under section 351 of the PHS Act, which will continue to be paid as biologicals" (90 FR 49490). Rates and coverage for 2026 are in our payment and coverage guide. CMS published its CY 2027 final rule (CMS-1848-F) in the Federal Register on 9 November 2026.
- It tells you which document to ask for.
CMS also notes: "The FDA has not defined the term 'skin substitute.'" (90 FR 49497). The FDA terms are the four below.
The four routes side by side
| Route | What happens before marketing | Word to expect | Where to look it up |
|---|---|---|---|
| 361 HCT/P | No premarket review. The establishment registers with FDA and lists its products. | Registered, listed | FDA's HCTERS public query |
| 510(k) device | FDA issues an order finding the device substantially equivalent to a legally marketed device. | Cleared, with a K number | FDA's 510(k) database |
| PMA device | FDA reviews scientific evidence and approves the application. | Approved, with a P number | FDA's PMA database |
| BLA biological product | FDA licenses the product under section 351 of the Public Health Service Act. | Licensed, with a BLA number | FDA's Purple Book |
FDA also has a De Novo route for novel devices. If a manufacturer cites it, ask for that number in the same way.
361 HCT/P: registered is not approved
Under 21 CFR 1271.10(a), as read on 16 November 2026, an HCT/P is regulated solely under section 361 only if it meets all of the listed criteria. In short: it is minimally manipulated; it is "intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent"; it is not combined with another article, apart from limited exceptions such as water or a preserving agent; and it either has no systemic effect and does not depend on the metabolic activity of living cells, or falls within a short list of exceptions.
FDA's tissue Q&A says HCT/Ps that meet those criteria "are not required to be licensed, approved or cleared." The manufacturer registers and lists the product. Under 21 CFR 1271.27(b), acceptance of a registration and listing "does not constitute a determination that an establishment is in compliance with applicable rules and regulations or that the HCT/P is licensed or approved by FDA."
CMS's CY 2026 final rule says that when it refers to 361 HCT/Ps, "it generally refers to products where an establishment has self-determined that their product is a 361 HCT/P" (90 FR 49489).
- Read the intended use. In the same rule, CMS wrote that registered 361 HCT/Ps "generally are dressings intended only to cover and protect a wound" and that their "activity is typically limited to that of a physical covering or wrap" (90 FR 49496). If a brochure says more than the label and package insert do, ask the manufacturer to explain the difference in writing.
- Only human tissue can be a 361 HCT/P. The definition in 21 CFR 1271.3(d) excludes "Cells, tissues, and organs derived from animals other than humans". A fish skin or other animal-derived matrix, or a synthetic matrix with no human cells or tissue, is therefore not a 361 HCT/P. Ask which device route it took and for the number.
510(k) and PMA: cleared and approved are different words
FDA's 510(k) page explains that before marketing a device through this route, the submitter must receive an order from FDA "which finds the device to be substantially equivalent (SE) and states that the device can be marketed in the U.S. This order 'clears' the device for commercial distribution".
FDA describes premarket approval as "the most stringent type of device marketing application required by FDA", and says the applicant must receive FDA approval of its PMA application before marketing the device.
So a 510(k) product is cleared, a PMA product is approved, and neither word applies to a 361 HCT/P. Marketing copy that mixes them up is a reason to ask for the number.
How to check a product yourself
- Ask for the status and the number in writing from the manufacturer or your supplier.
- For a device, search the K or P number in FDA's 510(k) database or PMA database and confirm that the device name and the applicant match the product in front of you.
- For a 361 HCT/P, search the manufacturer in FDA's HCTERS public query and confirm that the establishment is registered and lists the tissue type.
- For a BLA product, search FDA's Purple Book, the agency's database of licensed biological products.
- Look up the HCPCS code in CMS's list. CMS posts a skin substitute product list on its Skin Substitutes page. The CY 2027 list, downloaded on 16 November 2026, has one file for sheet products and one for non-sheet products, and sets each HCPCS code against an FDA regulatory category: 510(k), PMA or 361 HCT/P (shown as HCT/P in the non-sheet file).
- File what you find, and check again when the product, its labeling or its code changes.
Two cautions from CMS about its own categories, both from the CY 2026 final rule (90 FR 49487). The categories "may reflect current FDA regulation but are not intended to imply that FDA has determined that a product meets any specific FDA statutory or regulatory requirements." And inclusion of a product in a payment file "does not necessarily imply that a determination has been made by CMS or its contractors that it is reasonable and necessary". A category is not a coverage decision.
How this fits with ordering from us
Total Wound Experts sources from multiple manufacturers and does not publish brand names. Ask on the clinic intake or your onboarding call for the current options, and ask the manufacturer for documentation of a product's status before you add it. The provider makes the product decision. The other documents worth requesting are in our questions to ask a skin substitute supplier.
Related pages
- Skin substitute payment and coverage in 2026
- Amniotic membrane skin substitutes
- Questions to ask a skin substitute supplier
- Fish skin grafts: what wound care clinics should know
Frequently asked questions
Does FDA approve a 361 HCT/P before it is sold?
No. FDA says HCT/Ps that meet the criteria in 21 CFR 1271.10 are not required to be licensed, approved or cleared. The manufacturer registers and lists the product, and under 21 CFR 1271.27(b) that registration does not constitute a determination that the HCT/P is licensed or approved by FDA.
What is the difference between 510(k) clearance and PMA approval?
A 510(k) order finds a device substantially equivalent to a device already legally marketed, and FDA says the order clears the device for commercial distribution. Premarket approval is a separate application that FDA describes as the most stringent type of device marketing application it requires.
Can a fish skin or other animal-derived product be a 361 HCT/P?
No. The definition of an HCT/P in 21 CFR 1271.3(d) covers human cells and tissues and excludes cells, tissues and organs derived from animals other than humans. Ask the manufacturer which device route the product took and for the number.
Where does CMS list the FDA category for a skin substitute HCPCS code?
On the Skin Substitutes page of cms.gov, in the skin substitute product list. The CY 2027 list sets each HCPCS code against a category of 510(k), PMA or 361 HCT/P. CMS says the categories are not intended to imply that FDA has determined a product meets any specific requirement.
Sources
Each source below was read on 16 Nov 2026.
- Fact sheet: CY 2026 Medicare Physician Fee Schedule final rule (CMS-1832-F), Centers for Medicare & Medicaid Services. Skin substitute categories aligned with FDA regulatory status.
- CY 2026 Physician Fee Schedule final rule, 90 FR 49266 (5 Nov 2025), Centers for Medicare & Medicaid Services, in the Federal Register. Pages 49487 to 49497: FDA categories, self-determination, intended use, BLA products, and the cautions about categories and payment files.
- Skin Substitutes, with the CY 2027 Skin Substitute Product List (ZIP), Centers for Medicare & Medicaid Services. HCPCS codes for sheet and non-sheet products set against an FDA regulatory category.
- CMS-1848-F, CY 2027 Physician Fee Schedule final rule, Centers for Medicare & Medicaid Services. Publication date of the CY 2027 final rule.
- 21 CFR 1271.10, HCT/Ps regulated solely under section 361, eCFR, Office of the Federal Register and Government Publishing Office. The criteria in paragraph (a) and the duty to register and list in paragraph (b).
- 21 CFR 1271.27, registration numbers, eCFR, Office of the Federal Register and Government Publishing Office. Paragraph (b): what acceptance of a registration does not mean.
- 21 CFR 1271.3, definitions, eCFR, Office of the Federal Register and Government Publishing Office. Paragraph (d): what is and is not an HCT/P.
- Tissue and Tissue Product Questions and Answers, U.S. Food and Drug Administration. Why not all HCT/Ps are licensed, approved or cleared.
- Premarket Notification 510(k), U.S. Food and Drug Administration. Substantial equivalence and what a clearance order is.
- Premarket Approval (PMA), U.S. Food and Drug Administration. What premarket approval is.
- Human Cell and Tissue Establishment Registration (HCTERS) Public Query Application, U.S. Food and Drug Administration. The public search for registered tissue establishments.
- About the Purple Book, U.S. Food and Drug Administration. FDA's database of licensed biological products.
Ready to order for your clinic?
Complete the clinic intake. We review it, schedule a 20-minute call and most clinics place a first order within a week.
This page is general information for licensed providers and practice staff. It is not billing, coding, legal, or medical advice. Coverage rules vary by payer, region, setting, and date of service; confirm current policy before treating or billing.